Li Linlin, Liang Jiahui, Zhang Huan, Guo Jing, Li Shan, Li Meng
Medical Science Laboratory, Children's Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, People's Republic of China.
Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
BMC Infect Dis. 2025 Jan 3;25(1):19. doi: 10.1186/s12879-024-10390-4.
In clinical practice, the emergence of ST11-K64 carbapenem-resistant Klebsiella pneumoniae (ST11-K64 CRKP) has become increasingly alarming. Despite this trend, limited research has been conducted to elucidate the clinical and molecular characteristics of these strains.
This study aimed to comprehensively investigate the clinical characteristics, antimicrobial resistance patterns, resistance and virulence-associated genes, and molecular epidemiology of ST11-K64 CRKP in Southwest China.
A retrospective analysis was performed on patients infected with carbapenem-resistant Klebsiella pneumoniae (CRKP) in a tertiary care hospital between July 2021 and May 2022. A total of 69 CRKP strains were isolated, with clinical data collected for detailed analysis. Laboratory assessments included antimicrobial susceptibility testing, hypermucoviscosity string testing, genotypic characterization of antimicrobial resistance and virulence genes, and multi-locus sequence typing. Statistical analyses were conducted using SPSS, with significance set at P < 0.05.
Among the 69 CRKP isolates, 36 strains (52.2%) were identified as ST11-K64 CRKP. Hematological diseases were less associated with ST11-K64 CRKP infection compared to non-ST11-K64 strains (P = 0.012). However, central intravenous catheter use (P = 0.001), mechanical ventilation (P = 0.002), tracheal intubation (P = 0.006), and tracheotomy (P = 0.041) were significantly more common in ST11-K64 CRKP cases. Resistance rates to amikacin (P < 0.001), gentamicin (P = 0.004), tobramycin (P = 0.034), and sulfamethoxazole (P < 0.001) were significantly higher in ST11-K64 CRKP. Additionally, resistance-associated genes such as bla (P < 0.001) and virulence-associated genes including rmpA (P < 0.001), iucA (P < 0.001), rmpA2 (P < 0.001), and iutA (P = 0.001) were detected at significantly higher rates in ST11-K64 strains compared to non-ST11-K64 strains. Furthermore, compared to ST11-K47 CRKP, ST11-K64 CRKP harbored more virulence genes, such as rmpA (P = 0.007), iucA (P = 0.001), and iutA (P = 0.003).
Our findings underscore the rising prevalence of ST11-K64 CRKP, characterized by high levels of antimicrobial resistance and the presence of potent resistance and virulence genes. This strain poses a significant clinical and therapeutic challenge, necessitating heightened vigilance, stringent infection control measures, and robust clinical management strategies.
在临床实践中,ST11-K64碳青霉烯耐药肺炎克雷伯菌(ST11-K64 CRKP)的出现日益引起关注。尽管有这一趋势,但针对这些菌株的临床和分子特征的研究却很有限。
本研究旨在全面调查中国西南部ST11-K64 CRKP的临床特征、抗菌药物耐药模式、耐药和毒力相关基因以及分子流行病学。
对2021年7月至2022年5月在一家三级医院感染碳青霉烯耐药肺炎克雷伯菌(CRKP)的患者进行回顾性分析。共分离出69株CRKP菌株,并收集临床数据进行详细分析。实验室评估包括抗菌药物敏感性测试、高黏液性拉丝试验、抗菌药物耐药和毒力基因的基因分型以及多位点序列分型。使用SPSS进行统计分析,显著性设定为P < 0.05。
在69株CRKP分离株中,36株(52.2%)被鉴定为ST11-K64 CRKP。与非ST11-K64菌株相比,血液系统疾病与ST11-K64 CRKP感染的相关性较小(P = 0.012)。然而,在ST11-K64 CRKP病例中,中心静脉导管使用(P = 0.001)、机械通气(P = 0.002)、气管插管(P = 0.006)和气管切开术(P = 0.041)明显更为常见。ST11-K64 CRKP对阿米卡星(P < 0.001)、庆大霉素(P = 0.004)、妥布霉素(P = 0.034)和磺胺甲恶唑(P < 0.001)的耐药率显著更高。此外,与非ST11-K64菌株相比,ST11-K64菌株中耐药相关基因如bla(P < 0.001)和毒力相关基因包括rmpA(P < 0.001)、iucA(P < 0.001)、rmpA2(P < 0.001)和iutA(P = 0.001)的检出率显著更高。此外,与ST11-K47 CRKP相比,ST11-K64 CRKP携带更多毒力基因,如rmpA(P = 0.007)、iucA(P = 0.001)和iutA(P = 0.003)。
我们的研究结果强调了ST11-K64 CRKP的患病率不断上升,其特点是高水平的抗菌药物耐药性以及存在强效的耐药和毒力基因。该菌株带来了重大的临床和治疗挑战,需要提高警惕、采取严格的感染控制措施和强有力的临床管理策略。